2023 /PRNewswire/ -- Today, May 25, 2023, the annual general meeting (the
"AGM") of Implantica AG (publ) was held in Ruggel, Liechtenstein. The general meeting resolved to
adopt all of the board of directors' resolution proposals. A
summary of the resolutions adopted at the general meeting is set
The general meeting adopted the annual report 2022 consisting of
the statutory financial statements and the consolidated financial
statements of Implantica AG for the financial year 2022,
acknowledging the reports of the auditors.
The general meeting resolved to carry forward the net loss for
the financial year 2022 in accordance with the adopted balance
sheet and to no payment of dividend.
The general meeting resolved to discharge the members of the
board of directors, the executive management and the auditors from
liability for their services in the financial year 2022.
The general meeting resolved to approve the total remuneration
of the board of directors of CHF 109
thousand and of the executive management of CHF 754 thousand for the financial year 2022. The
total remuneration includes fixed compensation and pension
contributions. Executive Management is made up of the Chief
Executive Officer, Chief Strategy Officer, Chief Financial Officer
and Chief Corporate Affairs Officer.
The general meeting resolved to re-elect Liselott Kilaas, Johan Bojs, Tomas Puusepp, Klaus Neftel and Stephan Siegenthaler as board members for a term
of office until completion of the next AGM of shareholders.
Liselott Kilaas was also re-elected
as chairman and Johan Bojs was re-elected as vice-chairman of the
board of directors until the end of the next annual general
The general meeting resolved to re-elect Johan Bojs as member
and chairman and Klaus Neftel as member of the nomination and
remuneration committee until completion of the next AGM.
The general meeting resolved to re-elect Philipp Wanger, Attorney-at-law, Neugasse 17,
9490 Vaduz, Liechtenstein as
independent proxy until the next general meeting of
The general meeting resolved to re-elect KPMG (Liechtenstein) AG, Aulestrasse 2, 9490 Vaduz,
Liechtenstein as auditor for the
financial year 2023.
The minutes of the annual general meeting with information
regarding each resolution proposal adopted at the general meeting
will be available at www.implantica.com.
For further information, please contact:
Nicole Pehrsson, Chief Corporate
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528
00 399, firstname.lastname@example.org
The information was sent for publication, through the agency
of the contact person set out above, on May
25, 2023 at 20:45 CET.
Implantica is a medtech group dedicated to bringing advanced
technology into the body. Implantica's lead product, RefluxStop™,
is a CE-marked implant for the prevention of gastroesophageal
reflux that will potentially create a paradigm shift in anti-reflux
treatment as supported by successful clinical trial results.
Implantica also focuses on eHealth inside the body and has
developed a broad, patent protected, product pipeline based partly
on two platform technologies: an eHealth platform designed to
monitor a broad range of health parameters, control treatment from
inside the body and communicate to the caregiver on distance and a
wireless energising platform designed to power remote controlled
implants wirelessly through intact skin. Implantica is listed on
Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit
www.implantica.com for further information.
The following files are available for download:
Bulletin from the
Annual General Meeting of Implantica AG